Biora Therapeutics, Inc

Longboard Pharmaceuticals delivers medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. Its proprietary pipeline includes multiple programs with broad clinical utility. Longboard is evaluating LP352, a next-generation 5-HT2C agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or DEEs. Longboard is also evaluating LP143, a centrally acting, full agonist of the cannabinoid type 2 receptor (CB2), and LP659, a centrally acting, next-generation, highly selective S1P receptor modulator.

Aardvark Therapeutics, Inc. is a biotechnology company based in San Diego, CA, specializing in innovative therapeutic programs. The company is dedicated to advancing science and creating impactful health solutions through strategic partnerships and investments. With a team committed to excellence, Aardvark Therapeutics focuses on addressing unmet medical needs and fostering collaboration within the industry. Their efforts are geared towards driving meaningful advancements in healthcare and improving patient outcomes. Generated from the website

Calidi Biotherapeutics, Inc., based in San Diego, CA, is a clinical-stage biotechnology company focused on developing innovative targeted immunotherapies aimed at solid tumors. Their unique approach utilizes off-the-shelf stem cells that deliver viral payloads to eliminate cancer cells locally while enhancing the immune system's ability to combat metastatic disease. By transforming immunologically cold tumors into hot ones, Calidi aims to help the immune system recognize and attack cancer cells more effectively. With a dedicated team of experts, the company is committed to pioneering new solutions in the fight against cancer and redefining treatment paradigms in oncology. Generated from the website